Aethlon Medical Inc
$ 2.00
1.27%
24 Feb - close price
- Market Cap 2,636,800 USD
- Current Price $ 2.00
- High / Low $ 2.02 / 1.92
- Stock P/E N/A
- Book Value 6.90
- EPS -48.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.63 %
- ROE -2.09 %
- 52 Week High 47.92
- 52 Week Low 1.86
About
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-12 | 2025-08-12 | 2025-06-27 | 2025-02-12 | 2024-11-12 | 2024-08-14 | 2024-06-26 | 2024-02-14 | 2023-11-14 | 2023-08-10 | 2023-06-28 |
| Reported EPS | -2.45 | -3.74 | -0.85 | -3.44 | -0.13 | -0.2 | -0.34 | -0.91 | -1.37 | -1.22 | -0.14 | -0.1 |
| Estimated EPS | -2.01 | -1.08 | -0.73 | -1.11 | -0.2033 | -0.19 | -0.31 | -1.25 | -1.23 | -1.4 | -0.13 | -0.13 |
| Surprise | -0.44 | -2.66 | -0.12 | -2.33 | 0.0733 | -0.01 | -0.03 | 0.34 | -0.14 | 0.18 | -0.01 | 0.03 |
| Surprise Percentage | -21.8905% | -246.2963% | -16.4384% | -209.9099% | 36.0551% | -5.2632% | -9.6774% | 27.2% | -11.3821% | 12.8571% | -7.6923% | 23.0769% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AEMD
2026-02-23 13:16:38
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the Emerging Growth Conference on February 25, 2026, from 12:30-1:00 PM ET. The interactive online event provides an opportunity for investors to engage with the Company's CEO and CFO, Jim Frakes, who will host a fireside chat and Q&A session. Aethlon is focused on developing its investigational Hemopurifier device to treat cancer and life-threatening infectious diseases.
2026-02-23 13:06:21
Aethlon Medical (Nasdaq: AEMD) is scheduled to present at the Emerging Growth Conference on February 25, 2026, offering a live, interactive fireside chat with CEO and CFO Jim Frakes and a real-time Q&A for investors. The presentation aims to update the investment community on the company's developments, including its Hemopurifier device, which has received FDA Breakthrough Device Designation. Recent company history shows mixed investor reactions to news, with positive clinical data driving gains while earnings and financing announcements have had negative impacts.
2026-02-21 06:56:44
Aethlon Medical (NASDAQ: AEMD) is a clinical-stage biotechnology company focused on developing immunotherapeutic medical devices. Its lead product, the Hemopurifier®, aims to remove viruses and exosomes from the bloodstream to restore immune function for oncology and infectious disease patients. The company has a consensus analyst rating of "Reduce" with a price target of $560.00, despite negative projected earnings.
2026-02-16 05:04:35
Aethlon Medical Inc (AEMD) reported progress in its Q3 2026 earnings call, highlighting advancements in its Australian oncology trial, including the successful completion of the first cohort and ongoing treatments in the second. The company is also expanding its extracellular vesicle research and working on hemopurifier compatibility with a simplified blood treatment system. Despite increased operating expenses and a higher operating loss compared to the previous year, AEMD maintains a stable financial position with a cash balance of approximately $7 million.
2026-02-14 13:28:04
Aethlon Medical, Inc. (NASDAQ:AEMD) discussed its Q3 2026 earnings, reporting a miss on EPS expectations at $-2.45 compared to an expected $-2.01. The company provided an update on its Australian oncology trial for the Hemopurifier, noting progress in patient enrollment and treatment for solid tumors. They also highlighted advancements in their extracellular vesicle research, compatibility studies with a simplified blood treatment system, and disciplined cost control measures.
2026-02-13 19:57:16
Aethlon Medical (AEMD) reported Q3 2026 financial results, highlighting significant progress in its oncology trials in Australia, with the second cohort underway. Despite operational strides, the company faces financial challenges, including a 13.6% increase in operating expenses year-over-year and negative future earnings projections, leading to a 6.7% stock decline in aftermarket trading. Aethlon is also exploring new applications for its Hemopurifier platform and compatibility with a simplified blood treatment system to expand accessibility.
